SynRG Brings its Business to the U.S.
Synergy Research Group (SynRG) is moving its business development center to the United States. The company's new Director of Business Development will be located in North Kingstown, RI.
The company hopes that in the current situation Russia will be even more attractive in terms of clinical trials for American small and mid-sized sponsors.
“We have always emphasized that one of the strategic goals set by SynRG is enhancing of research and investment attractiveness of Russia for foreign sponsors, so business development in the USA is a natural step along this strategic line," says SynRG CEO Igor Stefanov. “We spent quite some time interviewing candidates and conversing with the finalists, and now I am happy to introduce our new Director of Business Development, Anna Ravdel."
Anna Ravdel has graduated from the University of Manchester with an MBA degree, and worked as a marketing and sales director in various international companies. Prior to joining SynRG, Anna had worked as a Director of Business Development at Evidence Clinical and Pharmaceutical Research (Russia/USA) and at a global CRO Worldwide Clinical Trials.
SynRG also has plans of opening a Ukrainian office and, probably, a virtual office in Prague, as more and more of their clients are interested in the presence from Eastern European countries to Kazakhstan on a regional level.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
